The Patent Finder
US

Ferric Organic Compounds, Uses Thereof and Methods of Making Same

US 8,338,642 Term ended
OverviewFamilyAssignmentsSources & methods

Term ended Feb 18, 2024 · High confidence

USPTO later recorded it as expired for non-payment on Jan 27, 2025.

Filed Feb 24, 2010 as application 12/711,679 · Granted Dec 25, 2012
Base term plus 270 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
20 years from filing
Term ended Feb 18, 2024
2004 2026
Clock starts
Feb 18, 2004
Term ended
Feb 18, 2024
Granted
Dec 25, 2012
base term after the term ends fee events Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
270
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 7,767,851.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
25
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term runs 270 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Feb 18, 2004, when application PCT/US2004/004646, the earliest non-provisional in its chain, was filed (this one was filed Feb 24, 2010)Feb 18, 2024High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustment+270 days, USPTO patent term adjustment recordNov 14, 2024High confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 7,767,851)capped to Feb 18, 2024High confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events2 of 2 maintenance fees paidterm endedHigh confidence
USPTO status recordRecorded as expired for non-payment on Jan 27, 2025, after the term endedno changeHigh confidence
Computed term endThe steps above, in orderFeb 18, 2024High confidence

This family

Application PCT/US2004/004646PCT application
no patent term
no patent term
US 7,767,851Term ended
Feb 2024
Feb 2024
US 8,093,423In force
Oct 2028
Oct 2028
US 8,338,642this patent
Feb 2024
Feb 2024
US 8,299,298Term ended
Feb 2024
Feb 2024
US 8,754,257Term ended
Feb 2024
Feb 2024
US 8,609,896Term ended
Feb 2024
Feb 2024
US 8,754,258Term ended
Feb 2024
Feb 2024
8 of 25 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jan 28, 2013
Reel 29705, frame 165
Kwok, David W.k.; Stoynov, Nikolay MintchevPanion & BF Biotech, Inc.Assignment of Assignor's Interest
Feb 6, 2014
Reel 32161, frame 24
Kwok, David W.k.; Stoynov, Nikolay MintchevPanion & BF Biotech Inc.Assignment of Assignor's Interest
Feb 6, 2014
Reel 32161, frame 506
Panion & BF Biotech Inc.Globoasia LLCAssignment of Assignor's Interest
Feb 6, 2014
Reel 32161, frame 815
Globoasia LLCPanion & BF Biotech Inc.Nunc Pro Tunc Assignment
Apr 2, 2020
Reel 52295, frame 662
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCSecurity Interest
Sep 2, 2020
Reel 53671, frame 221
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCSecond Amended and Restated Intellectual Property Security Agreement
Sep 10, 2020
Reel 54173, frame 451
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCThird Amended and Restated Intellectual Property Security Agreement
Dec 17, 2020
Reel 54793, frame 455
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCFourth Amended and Restated Intellectual Property Security Agreement
Mar 30, 2021
Reel 55776, frame 491
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCFifth Amended and Restated Intellectual Property Security Agreement
Jun 11, 2021
Reel 56544, frame 468
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCSixth Amended and Restated Intellectual Property Security Agreement
Sep 12, 2021
Reel 57474, frame 770
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCSeventh Amended and Restated Intellectual Property Security Agreement
Dec 15, 2021
Reel 58399, frame 55
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCSecurity Interest
Jun 16, 2022
Reel 60529, frame 168
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCTenth Amended and Restated Intellectual Property Security Agreement
Aug 22, 2022
Reel 61297, frame 238
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCEleventh Amended and Restated Intellectual Property Security Agreement
Nov 29, 2022
Reel 62012, frame 561
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCTwelfth Amended and Restated Intellectual Property Security Agreement
Mar 29, 2023
Reel 63189, frame 65
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCThirteenth Amended and Restated Intellectual Property Security Agreement
Jan 4, 2024
Reel 66205, frame 143
Akebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Biopharma Credit PLCFifteenth Amended and Restated Intellectual Property Security Agreement
Jan 29, 2024
Reel 66377, frame 741
Biopharma Credit PLCAkebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Termination and Release of Security Interest in Patents
Jan 29, 2024
reel/frame not recorded
Biopharma Credit PLCAkebia Therapeutics, Inc.Termination and Release of Security Interest in Patents
Jan 29, 2024
reel/frame not recorded
Biopharma Credit PLCKeryx Biopharmaceuticals, Inc.Termination and Release of Security Interest in Patents
Jun 25, 2024
Reel 67839, frame 134
Biopharma Credit PLCAkebia Therapeutics, Inc.; Keryx Biopharmaceuticals, Inc.Termination and Release of Security Interest in Patents
Jun 25, 2024
reel/frame not recorded
Biopharma Credit PLCAkebia Therapeutics, Inc.Termination and Release of Security Interest in Patents
Jun 25, 2024
reel/frame not recorded
Biopharma Credit PLCKeryx Biopharmaceuticals, Inc.Termination and Release of Security Interest in Patents

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited